🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
REGN
NASDAQ
🇺🇸 US
Regeneron Pharmaceuticals, Inc.
Pharmaceuticals
33Score
DipBuster Score™
$672.15
$4.54 (-0.67%)
Live price · Source: Yahoo
52-Week Position
$541.00
47% of range
$821.11
Beta
0.236
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.236
52W High$821.11
52W Low$541.00
DipBuster Brief
Key signals at a glance
Zone: Hold / Watch
Neutral
Mid-Range Position (47% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position47% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.236
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Regeneron Pharmaceuticals, Inc. (REGN), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-07-02 | Ryan Arthur F | SELL | 200 |
| 2026-05-01 | Ryan Arthur F | SELL | 2 |
| 2026-05-01 | Ryan Arthur F | SELL | 1 |
| 2026-05-01 | Ryan Arthur F | SELL | 5 |
| 2026-05-01 | Ryan Arthur F | SELL | 2 |
| 2026-05-01 | Ryan Arthur F | SELL | 6 |
| 2026-05-01 | Ryan Arthur F | SELL | 4 |
| 2026-05-01 | Ryan Arthur F | SELL | 7 |
| 2026-05-01 | Ryan Arthur F | SELL | 14 |
| 2026-05-01 | Ryan Arthur F | SELL | 15 |
Graham NCAV Analysis
Above net-net level
Current Assets$18.02B
Less: Total Liabilities−$9.30B
= Net Current Asset Value$8.72B
NCAV Per Share$62.5468
Current Price$670.36
Price / NCAV10.72×
Margin of Safety-971.8%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.236
Dividend/yrNone
52W High$821.11
52W Low$541.00
52-Week Range
$541.00Now$821.11
47% through annual range
From 52W High−18.1%
From 52W Low+24.2%
📖 Plain English Summary
Regeneron Pharmaceuticals, Inc. is at 47% of its 52-week range. Beta 0.236 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for REGN
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — REGN
Heuristic · balance sheet, insider filings, price data, academic research
Regeneron Pharmaceuticals, Inc. — DipBuster Score 33/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Regeneron Pharmaceuticals, Inc. free
Add REGN to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
21/25
Momentum & Volume
7/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
14
/100 · NEUTRAL
dip depth
14/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 33/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeu…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Leonard S. Schleifer
Staff
15,410 employees
Website